Literature DB >> 20521126

Abacavir and cardiovascular risk: reviewing the evidence.

Dominique Costagliola1, Sylvie Lang, Murielle Mary-Krause, Franck Boccara.   

Abstract

Since the presentation of the D:A:D study results at the Conference on Retroviruses and Opportunistic Infections in February 2008, 10 studies have explored the association between exposure to abacavir and the risk of myocardial infarction. Among the five larger studies, three conclude that there is an association and two that the association is not robust. Based on these studies, it is impossible to refute or confirm a causal relationship, as it is not possible to exclude remaining confounding (smoking in two of the studies, kidney function in two of the studies, cocaine and/or intravenous drug use) and selection bias in studies that report a robust association. In addition, no convincing mechanism has been described.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20521126     DOI: 10.1007/s11904-010-0047-3

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  15 in total

1.  Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy.

Authors:  Dominique Costagliola
Journal:  C R Biol       Date:  2007-04-06       Impact factor: 1.583

2.  Vascular complications associated with use of HIV protease inhibitors.

Authors:  B Gallet; M Pulik; P Genet; P Chedin; M Hiltgen
Journal:  Lancet       Date:  1998-06-27       Impact factor: 79.321

3.  Severe premature coronary artery disease with protease inhibitors.

Authors:  K Henry; H Melroe; J Huebsch; J Hermundson; C Levine; L Swensen; J Daley
Journal:  Lancet       Date:  1998-05-02       Impact factor: 79.321

4.  Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.

Authors:  Cindy H Brothers; Jaime E Hernandez; Amy G Cutrell; Lloyd Curtis; Mounir Ait-Khaled; Steve J Bowlin; Sara H Hughes; Jane M Yeo; Didier H Lapierre
Journal:  J Acquir Immune Defic Syndr       Date:  2009-05-01       Impact factor: 3.731

5.  Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

Authors:  Allison Martin; Mark Bloch; Janaki Amin; David Baker; David A Cooper; Sean Emery; Andrew Carr
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

6.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

7.  Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.

Authors:  Niels Obel; D K Farkas; G Kronborg; C S Larsen; G Pedersen; A Riis; C Pedersen; J Gerstoft; H T Sørensen
Journal:  HIV Med       Date:  2009-08-13       Impact factor: 3.180

8.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Authors:  Kimberly Y Smith; Parul Patel; Derek Fine; Nicholaos Bellos; Louis Sloan; Philip Lackey; Princy N Kumar; Denise H Sutherland-Phillips; Cindy Vavro; Linda Yau; Paul Wannamaker; Mark S Shaefer
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

9.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

10.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

View more
  13 in total

Review 1.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

2.  N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo.

Authors:  C Charneira; N M Grilo; S A Pereira; A L A Godinho; E C Monteiro; M M Marques; A M M Antunes
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 3.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

4.  Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.

Authors:  Carl J Fichtenbaum
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

5.  Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.

Authors:  Benjamin Young; Kathleen E Squires; Lisa L Ross; Lizette Santiago; Louis M Sloan; Henry H Zhao; Brian C Wine; Gary E Pakes; David A Margolis; Mark S Shaefer
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-05       Impact factor: 2.205

6.  Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.

Authors:  Kunchok Dorjee; Tsering Choden; Sanjiv M Baxi; Craig Steinmaus; Arthur L Reingold
Journal:  Int J Antimicrob Agents       Date:  2018-07-21       Impact factor: 5.283

Review 7.  Can early therapy reduce inflammation?

Authors:  Netanya G Sandler; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2014-01       Impact factor: 4.283

8.  Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.

Authors:  Amit C Achhra; Mark A Boyd
Journal:  AIDS Res Ther       Date:  2013-12-13       Impact factor: 2.250

9.  Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Authors:  Amit C Achhra; Mark A Boyd; Matthew G Law; Gail V Matthews; Anthony D Kelleher; David A Cooper
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

10.  The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events.

Authors:  Gilles Wandeler; David Kraus; Jan Fehr; Anna Conen; Alexandra Calmy; Christina Orasch; Manuel Battegay; Patrick Schmid; Enos Bernasconi; Hansjakob Furrer
Journal:  J Acquir Immune Defic Syndr       Date:  2016-03-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.